$5.42 Billion is the total value of Redmile Group, LLC's 80 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was 20.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FOLD | Sell | AMICUS THERAPEUTICS INC | $376,166,000 | +61.7% | 24,944,695 | -0.9% | 6.94% | +6.5% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $297,342,000 | +41.2% | 4,978,941 | -2.7% | 5.49% | -7.0% |
| ARGX | Sell | ARGENX SEsponsored adr | $233,083,000 | +63.5% | 1,034,868 | -4.4% | 4.30% | +7.7% |
| ALLK | Sell | ALLAKOS INC | $188,207,000 | +42.1% | 2,619,080 | -12.0% | 3.47% | -6.4% |
| MNTA | Sell | MOMENTA PHARMACEUTICALS INC | $156,546,000 | +11.2% | 4,705,308 | -9.1% | 2.89% | -26.8% |
| EPZM | Sell | EPIZYME INC | $136,279,000 | +0.2% | 8,485,605 | -3.2% | 2.52% | -34.0% |
| ONEM | Sell | 1LIFE HEALTHCARE INC | $109,348,000 | +92.9% | 3,010,684 | -3.6% | 2.02% | +27.1% |
| BEAM | Sell | BEAM THERAPEUTICS INC | $93,995,000 | +55.4% | 3,356,958 | -0.1% | 1.74% | +2.4% |
| RGNX | Sell | REGENXBIO INC | $82,380,000 | +8.8% | 2,236,766 | -4.3% | 1.52% | -28.4% |
| NVRO | Sell | NEVRO CORP | $59,468,000 | -15.8% | 497,764 | -29.5% | 1.10% | -44.5% |
| TCDA | Sell | TRICIDA INC | $58,230,000 | +24.5% | 2,119,000 | -0.4% | 1.08% | -18.1% |
| QURE | Sell | UNIQURE NV | $56,196,000 | -57.3% | 1,247,135 | -55.0% | 1.04% | -71.9% |
| IMGN | Sell | IMMUNOGEN INC | $55,232,000 | -3.2% | 12,006,979 | -28.2% | 1.02% | -36.2% |
| SRRK | Sell | SCHOLAR ROCK HLDG CORP | $52,370,000 | +49.6% | 2,875,889 | -0.5% | 0.97% | -1.4% |
| BIIB | Sell | BIOGEN INC | $43,423,000 | -76.7% | 162,300 | -72.5% | 0.80% | -84.7% |
| AXNX | Sell | AXONICS MODULATION TECHNOLOG | $41,855,000 | +9.3% | 1,192,100 | -20.9% | 0.77% | -28.0% |
| MRK | Sell | MERCK & CO. INC | $40,544,000 | -33.2% | 524,300 | -33.5% | 0.75% | -56.0% |
| DXCM | Sell | DEXCOM INC | $39,445,000 | +13.3% | 97,300 | -24.7% | 0.73% | -25.4% |
| NVS | Sell | NOVARTIS AGsponsored adr | $38,412,000 | -28.7% | 439,800 | -32.7% | 0.71% | -53.1% |
| GMAB | Sell | GENMAB A/Ssponsored ads | $35,835,000 | +9.2% | 1,057,393 | -31.7% | 0.66% | -28.0% |
| UNH | Sell | UNITEDHEALTH GROUP INC | $30,645,000 | -49.0% | 103,900 | -56.9% | 0.57% | -66.4% |
| CTLT | Sell | CATALENT INC | $30,280,000 | +15.1% | 413,100 | -18.4% | 0.56% | -24.2% |
| EIDX | Sell | EIDOS THERAPEUTICS INC | $28,308,000 | -16.2% | 593,842 | -13.9% | 0.52% | -44.8% |
| ZYME | Sell | ZYMEWORKS INC | $28,261,000 | -8.3% | 783,500 | -9.8% | 0.52% | -39.6% |
| PRAH | Sell | PRA HEALTH SCIENCES INC | $27,177,000 | -26.1% | 279,336 | -36.9% | 0.50% | -51.3% |
| TCRR | Sell | TCR2 THERAPEUTICS INC | $27,113,000 | +98.2% | 1,765,188 | -0.1% | 0.50% | +30.8% |
| ODT | Sell | ODONATE THERAPEUTICS INC | $26,803,000 | +37.1% | 633,038 | -10.6% | 0.50% | -9.7% |
| TWST | Sell | TWIST BIOSCIENCE CORP | $26,695,000 | +47.9% | 589,300 | -0.2% | 0.49% | -2.6% |
| ARDX | Sell | ARDELYX INC | $24,318,000 | +9.6% | 3,514,100 | -10.0% | 0.45% | -27.8% |
| HOOK | Sell | HOOKIPA PHARMA INC | $21,620,000 | +40.7% | 1,860,610 | -0.1% | 0.40% | -7.4% |
| BCEL | Sell | ATRECA INC | $21,111,000 | +13.0% | 992,068 | -12.1% | 0.39% | -25.6% |
| GRTS | Sell | GRITSTONE ONCOLOGY INC | $20,352,000 | +14.0% | 3,064,994 | -0.1% | 0.38% | -25.0% |
| AKRO | Sell | AKERO THERAPEUTICS INC | $9,772,000 | -19.1% | 392,152 | -31.1% | 0.18% | -46.7% |
| XERS | Sell | XERIS PHARMACEUTICALS INC | $6,377,000 | +10.6% | 2,397,441 | -18.9% | 0.12% | -27.2% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $5,844,000 | +43.6% | 1,674,447 | -39.1% | 0.11% | -5.3% |
| WVE | Sell | WAVE LIFE SCIENCES LTD | $4,322,000 | -84.2% | 415,155 | -85.8% | 0.08% | -89.6% |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -253,516 | -100.0% | -0.02% | – |
| CLVS | Exit | CLOVIS ONCOLOGY INC | $0 | – | -99,485 | -100.0% | -0.02% | – |
| GOSS | Exit | GOSSAMER BIO INC | $0 | – | -259,700 | -100.0% | -0.07% | – |
| RVMD | Exit | REVOLUTION MEDICINES INC | $0 | – | -303,371 | -100.0% | -0.19% | – |
| ADPT | Exit | ADAPTIVE BIOTECHNOLOGIES COR | $0 | – | -414,400 | -100.0% | -0.32% | – |
| SWAV | Exit | SHOCKWAVE MED INC | $0 | – | -557,800 | -100.0% | -0.52% | – |
| CNC | Exit | CENTENE CORP DEL | $0 | – | -824,090 | -100.0% | -1.37% | – |
| TNDM | Exit | TANDEM DIABETES CARE INC | $0 | – | -881,266 | -100.0% | -1.59% | – |
| SGEN | Exit | SEATTLE GENETICS INC | $0 | – | -655,700 | -100.0% | -2.12% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.